Trial · NCT04581356
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Peak oxygen consumption (VO2) | 8 weeks | Change in peak oxygen consumption (VO2) measured in CPET after voxelotor treatment |
| Secondary | Change in Biochemical markers of red cell sickling: Hemoglobin | 8 weeks | Measured before and after treatment with voxelotor. |
| Secondary | Change in Biochemical markers of red cell sickling: Reticulocyte Count | 8 weeks | Measured before and after treatment with voxelotor. |
| Secondary | Change in Biochemical markers of red cell sickling: Bilirubin | 8 weeks | Measured before and after treatment with voxelotor. |
| Secondary | Change in Biochemical markers of red cell sickling: Lactate Dehydrogenase (LDH) | 8 weeks | Measured before and after treatment with voxelotor. |
| Secondary | Change in Biochemical markers of red cell sickling: Haptoglobin | 8 weeks | Measured before and after treatment with voxelotor. |
| Secondary | Change in Biochemical markers of red cell sickling: % Fetal Hemoglobin expressing cells | 8 weeks | Measured before and after treatment with voxelotor. |
| Secondary | Change in Biochemical markers of red cell sickling: P50 oxygen dissociation | 8 weeks | Measured before and after treatment with voxelotor. |
| Secondary | Change in Biochemical markers of red cell sickling: Point of Sickling (POS) | 8 weeks | Measured before and after treatment with voxelotor. |
| Secondary | Change in Biochemical markers of red cell sickling: Dense Cells | 8 weeks | Measured before and after treatment with voxelotor. |
| Other | HRQOL: Patient's Global Impression of Change (PGIC) | 8 weeks | Health-related quality of life (HRQoL) as assessed by patient reported outcome via Patient's Global Impression of Change (PGIC) at end of treatment study visit. The PGIC asks patients to rate their overall improvement relative to their baseline state at the beginning of the study on a 7-point scale. 1. No change (or condition has got worse) 2. Almost the same, hardly any change at all 3. A little better, but not noticeable change at all 4. Somewhat better, but the change has not made any real difference 5. Moderately better, and a slight but noticeable change 6. Better, and a definite improvement that has made a real and worthwhile difference 7. A great deal better, and a considerable improvement that has made all the difference |
| Other | HRQOL: Clinical Global Impression of Change (CGIC) | 8 weeks | Health-related quality of life (HRQoL) as assessed by clinician-reported outcome via Clinical Global Impression of Change-Improvement (CGIC-I) scale at end of treatment study visit. The CGIC-I is a one-item questionnaire that requires the clinician to assess how much the patient's illness has improved or worsened relative to their baseline state at the beginning of the intervention on a 7-point scale: 1. = Very much improved 2. = Much improved 3. = Minimally improved 4. = No change 5. = Minimally worse 6. = Much worse 7. = Very much worse |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04581356/registered